MÅNEDLIG MÆNGDERAPPORT: TILBAGEKOMST AF PASSAGERER PÅ SPORET
| INVESTOR NEWS nr. 13 - 12. april 2022 |
Færge – fragt: For de sidste 12 måneder 2022-21 steg de samlede transporterede fragt-lanemeter 5,9% til 43,6 mio. fra 41,2 mio. i 2021-20.
De samlede mængder i marts 2022 var 0,3% højere end i 2021 (på niveau justeret for ruteændringer), idet højere mængder i North Sea, Mediterranean og Channel blev opvejet af lavere mængder i Baltic Sea.
North Seas mængder var lidt højere end i 2021. Mediterraneans mængder var samlet set en del højere end i 2021. Mod slutningen af marts blev mængderne på ruterne på Den Engelske Kanal øget på grund af en konkurrents suspendering af sejladser.
Baltic Seas mængder var lavere end i 2021 som følge af krigen i Ukraine. Mængderne var desuden påvirket af en reduktion af kapaciteten på en rute med én færge.
Færge - passager: Antallet af passagerer fortsatte med at stige i marts på baggrund af tilbagerulningen af rejserestriktioner. Antallet af passagerer steg mere end 400% til 134 tusind svarende til 49% af antallet af passagerer i marts 2019, den seneste sammenlignelige måned før Covid-19. Mængderne steg primært mellem Norge og Danmark samt på Kanalen.
For de sidste tolv måneder 2022-21 var det samlede antal passagerer 1,1 mio. sammenlignet med 1,0 mio. i 2021-20 og 5,1 mio. i 2019. Sidstnævnte er det seneste hele år før Covid-19.
| DFDS færgemængder | |||||||||
| Marts | Sidste tolv måneder | ||||||||
| Fragt | 2020 | 2021 | 2022 | Ændr. | 2020-19 | 2021-20 | 2022-21 | Ændr. | |
| Lanemeter, '000 | 3.553 | 4.028 | 4.039 | 0,3% | 40.781 | 41.199 | 43.618 | 5,9% | |
| Passager | 2020 | 2021 | 2022 | Ændr. | 2020-19 | 2021-20 | 2022-21 | Ændr. | |
| Passagerer, '000 | 112 | 25 | 134 | 431,6% | 4.963 | 1.002 | 1.070 | 6,8% | |
DFDS rapporterer månedlige færgemængder for fragt og passagerer med henblik på at give yderligere indsigt i trends for mængdeudviklingen i DFDS’ europæiske rutenetværk.
DFDS’ færgeruter muliggør varehandel og rejser i og omkring Europa. Klik på link for at se et kort over det samlede netværk. Mængder for april 2022 forventes offentliggjort 11. maj 2022 omkring kl 8.00.
Kontakt
Torben Carlsen, CEO
+45 33 42 32 01
Karina Deacon, CFO
+45 33 42 33 42
Søren Brøndholt Nielsen, IR
+45 33 42 33 59
Nicole Seroff, Communications
+45 31 40 34 46
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde
Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release
ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin
Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of